IMARC Group, a leading market research company, has recently released a report titled "Preterm Birth and PROM Testing Market Report by Test Type (Pelvic Exam, Ultrasound, Biochemical Markers, Uterine Monitoring, Nitrazine Test, Ferning Test, Pooling, PAMG-1 Immunoassay, IGFBP Test, Fetal Fibronectin (fFN), and Others), Application (PROM, Preterm Labor, Chorioamnionitis), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2024-2032". The study provides a detailed analysis of the industry, including the preterm birth and prom testing market trends, size, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global preterm birth and PROM testing market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/preterm-birth-prom-testing-market/requestsample
Factors Affecting the Growth of the Preterm Birth and PROM Testing Industry:
- Rising Prevalence of Preterm Births:
Preterm births, defined as deliveries occurring before 37 weeks of gestation, are a leading cause of neonatal morbidity and mortality worldwide. Factors such as maternal age, lifestyle changes, and underlying health conditions like diabetes and hypertension contribute to the rising incidence of preterm births. Additionally, the increase in multiple pregnancies due to assisted reproductive technologies (ART) has heightened the risk of preterm deliveries. This growing prevalence has spurred demand for early and accurate diagnostic tools to predict and manage preterm labor, supporting the market for preterm birth and PROM testing.
- Advancements in Diagnostic Technologies:
Technological innovations in diagnostic testing have been crucial in the development of more accurate, reliable, and rapid tests for preterm birth and PROM. Biomarkers such as fetal fibronectin (fFN), insulin-like growth factor-binding protein-1 (IGFBP-1), and placental alpha-microglobulin-1 (PAMG-1) have become pivotal in these tests, offering enhanced sensitivity and specificity in predicting preterm labor and detecting PROM. Point-of-care testing (POCT) has also seen significant growth, allowing for quicker results that can be used in clinical decision-making. The integration of these advanced diagnostic tools into prenatal care protocols has improved patient outcomes as healthcare providers seek to adopt the latest technologies to ensure better maternal and fetal health management, thus bolstering the market growth.
- Increased Awareness and Focus on Maternal and Fetal Health:
There has been a substantial increase in awareness regarding the importance of maternal and fetal health, driven by public health initiatives, education campaigns, and advocacy by healthcare professionals and organizations. This heightened awareness has led to more pregnant women seeking prenatal care, where early screening for potential complications like preterm birth and PROM is a critical component. Governments and healthcare systems in various regions have also prioritized maternal and child health, leading to improved access to prenatal services, including testing for preterm birth risks and PROM. Furthermore, the availability of insurance coverage for these tests in many countries has facilitated their widespread adoption, as more patients are able to afford these crucial diagnostics, thus contributing to the market growth.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=8617&flag=C
Preterm Birth and PROM Testing Market Report Segmentation:
By Test Type:
- Pelvic Exam
- Ultrasound
- Biochemical Markers
- Interleukin (IL)-6
- C-Reactive Protein (CRP)
- IL-1, IL-2, IL-8, TNF-a
- Corticotropin-Releasing Hormone (CRH)
- Alpha-fetoprotein (AFP)
- Uterine Monitoring
- Nitrazine Test
- Ferning Test
- Pooling
- PAMG-1 Immunoassay
- IGFBP Test
- Fetal Fibronectin (fFN)
- Others
Ultrasound accounts for the majority of the shares due to its non-invasive nature and ability to provide real-time, detailed imaging for assessing fetal health and amniotic fluid levels.
By Application:
- PROM
- Preterm Labor
- Chorioamnionitis
Preterm labor holds the largest market share due to significant health implications for both mother and child, driving the demand for early and accurate diagnostic testing.
By End User:
- Hospitals
- Diagnostic Laboratories
- Others
Hospitals dominate the market due to healthcare settings equipped with the necessary infrastructure and specialized personnel to conduct comprehensive preterm birth and PROM testing.
Regional Insights:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America enjoys the leading position due to its advanced healthcare infrastructure, high healthcare spending, strong presence of key market players, and high awareness of prenatal care.
Global Preterm Birth and PROM Testing Market Trends:
The increasing healthcare investments in emerging economies, the expanding role of telemedicine in prenatal care, and growing collaborations between private companies and research institutions to develop novel diagnostic solutions tailored to diverse patient populations and varying healthcare infrastructures are strengthening the market growth. In line with this, the expansion of personalized medicine approaches, which tailor interventions based on individual risk profiles, and the rising availability of innovative, user-friendly home testing kits that empower patients to monitor their pregnancy health more actively and conveniently impelling the market expansion.
Top Companies Operated in Preterm Birth and PROM Testing Industry:
- Clinical Innovations LLC (Laborie Medical Technologies Inc.)
- Cooper Surgical Inc. (The Cooper Companies Inc.)
- Hologic Inc.
- IQ Products
- NX Prenatal Inc.
- Qiagen N.V
- Sera Prognostics
Key Highlights of the Report:
• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• Market Trends
• Market Drivers and Success Factors
• Impact of COVID-19
• Value Chain Analysis
• Comprehensive mapping of the competitive landscape
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
